Pacira BioSciences, Inc.
PCRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | 0.23 | -1.75 | -0.88 |
| FCF Yield | 20.52% | 8.94% | 6.55% | 3.00% |
| EV / EBITDA | 42.36 | 12.89 | 17.22 | 28.14 |
| Quality | ||||
| ROIC | -5.05% | 3.99% | 3.81% | 3.46% |
| Gross Margin | 75.69% | 72.64% | 70.11% | 74.10% |
| Cash Conversion Ratio | -1.90 | 3.69 | 9.13 | 2.99 |
| Growth | ||||
| Revenue 3-Year CAGR | 1.68% | 7.62% | 15.78% | 8.75% |
| Free Cash Flow Growth | 28.15% | 21.09% | 44.27% | 103.54% |
| Safety | ||||
| Net Debt / EBITDA | 12.43 | 2.80 | 4.70 | 4.77 |
| Interest Coverage | -4.43 | 5.06 | 1.69 | 3.10 |
| Efficiency | ||||
| Inventory Turnover | 1.36 | 1.77 | 2.07 | 1.42 |
| Cash Conversion Cycle | 286.33 | 232.31 | 201.92 | 293.95 |